Why Production Scheduling Is Often the Second Module Organizations Implement After Electronic Batch Records
Organizations implementing Electronic Batch Records (EBR) often see immediate improvements. Batch documentation becomes digital. Quality Assurance (QA) review cycles shrink from hours to minutes. Deviations surface earlier in the process. Audit preparation becomes significantly easier. For many organizations operating in FDA-regulated and GMP environments, this step alone can transform daily operations. But once documentation is no longer the slowest step in the process, another constraint becomes visible. Scheduling. Suddenly teams notice something unexpected: the manufacturing floor itself is not the bottleneck. Coordination is. Clean rooms remain idle while batches wait for resources. Equipment availability overlaps with other programs. Personnel with …
Autologous vs. Allogeneic Cell Therapies: Supply Chain Differences That Impact Scale and Compliance
Autologous and allogeneic cell therapies are often compared from a scientific or clinical perspective. For organizations responsible for manufacturing and delivery, however, the most meaningful differences appear in the supply chain. These therapies follow fundamentally different operational models. Treating them as minor variations of the same workflow is one of the most common reasons cell and gene therapy (CGT) supply chains struggle to scale. Across CMOs, CDMOs, and therapy developers, a consistent pattern has emerged: when supply chain design does not reflect the underlying therapy model, compliance risk increases, timelines extend, and teams rely on manual workarounds that were never …
